Aardvark Therapeutics, Inc.
AARD
$8.22
-$0.30-3.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 99.43% | 35.89% | 102.70% | 102.70% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 323.20% | 196.16% | 138.06% | 138.06% | |
| Operating Income | -323.20% | -196.16% | -138.06% | -138.06% | |
| Income Before Tax | -330.13% | -98.29% | -149.41% | -149.41% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -330.13% | -98.29% | -149.41% | -149.41% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -330.13% | -98.29% | -149.41% | -149.41% | |
| EBIT | -323.20% | -196.16% | -138.06% | -138.06% | |
| EBITDA | -- | -- | -- | -- | |
| EPS Basic | -319.80% | -97.09% | -148.80% | -148.80% | |
| Normalized Basic EPS | -302.94% | -156.73% | -228.22% | -228.22% | |
| EPS Diluted | -319.80% | -97.09% | -148.80% | -148.80% | |
| Normalized Diluted EPS | -302.94% | -156.73% | -228.22% | -228.22% | |
| Average Basic Shares Outstanding | 2.46% | 0.61% | 0.25% | 0.25% | |
| Average Diluted Shares Outstanding | 2.46% | 0.61% | 0.25% | 0.25% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |